SEC Form 10-K filed by Insight Molecular Diagnostics Inc.
$IMDX
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)
4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)
10-Q - Insight Molecular Diagnostics Inc. (0001642380) (Filer)
8-K - Insight Molecular Diagnostics Inc. (0001642380) (Filer)
8-K/A - Insight Molecular Diagnostics Inc. (0001642380) (Filer)
Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagementNortheast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC studyBooked research-use-only purchase by E.U. transplant center and APAC purchase expected in coming daysAnticipate significant U.S. orders to follow FDA marketing authorizationEncouraging dialogue with FDA supports expected authorization later in 2026 NASHVILLE, Tenn., May 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (NASDAQ:IMDX), today published the following letter to shareholders in conjunction with its
NASHVILLE, Tenn., May 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that it will report first quarter 2026 financial results after the market closes on Wednesday, May 13, 2026, then host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDX Q1 2026 Earnings Webinar. An archived replay will be available after the call concludes on iMDX's website within the Investors/Events & Presentations section here. About Insight Molecular Diagnostics Inc.Insight Molec
Positive real-world head-to-head data on GraftAssureTM assay to be presented at the 39th European Immunogenetics and Histocompatibility Conference (EFI2026), April 21–24, 2026 in Edinburgh, ScotlandThree posters to be presented at the 63rd European Renal Association (ERA) Congress, June 3–6, 2026 in Glasgow, ScotlandFavorable real-world evidence poster to be presented at the American Transplant Congress (ATC), June 20–24, 2026 in BostonUnaudited first quarter 2026 cash balance of $29.4 million is in line with year-end and Q4 2025 conference call guidanceCompany to host fireside chat and one-on-one meetings with investors at Needham Virtual Healthcare Conference on Wednesday, April 15th NAS
4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)
4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)
4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)
Dr. Nick Ioannou brings decades of academia, industry, and clinical experience in organ transplant, nephrology, cardiology, genetics, and oncology NASHVILLE, Tenn., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), or iMDx, today announced that it has appointed Dr. Nick Ioannou, M.D., MHA, to the position of Vice President, Medical Affairs. Dr. Ioannou is a physician-scientist with more than three decades of highly relevant experience spanning clinical practice, diagnostics, regulatory affairs, medical education, and medical affairs. His background includes over fifteen years of field-based collaboration with key opinion leaders across multiple therapeu
NASHVILLE, Tenn., May 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that it will report first quarter 2026 financial results after the market closes on Wednesday, May 13, 2026, then host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDX Q1 2026 Earnings Webinar. An archived replay will be available after the call concludes on iMDX's website within the Investors/Events & Presentations section here. About Insight Molecular Diagnostics Inc.Insight Molec
Positive real-world head-to-head data on GraftAssureTM assay to be presented at the 39th European Immunogenetics and Histocompatibility Conference (EFI2026), April 21–24, 2026 in Edinburgh, ScotlandThree posters to be presented at the 63rd European Renal Association (ERA) Congress, June 3–6, 2026 in Glasgow, ScotlandFavorable real-world evidence poster to be presented at the American Transplant Congress (ATC), June 20–24, 2026 in BostonUnaudited first quarter 2026 cash balance of $29.4 million is in line with year-end and Q4 2025 conference call guidanceCompany to host fireside chat and one-on-one meetings with investors at Needham Virtual Healthcare Conference on Wednesday, April 15th NAS
NASHVILLE, Tenn., March 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that it will report fourth quarter 2025 financial results after the market closes on Thursday, March 26, 2026. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDx Q4 2025 Earnings Webinar. An archived replay will be available after the call concludes on iMDx's website within the Investors/Events & Presentations section here. Attendance at 25th Annual Needham Virtual He